Dual antiplatelet therapy following percutaneous coronary intervention: Clinical and economic impact of standard versus extended duration
Dual antiplatelet therapy (DAPT) -- the combination of a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) together with ASA -- is routinely given following percutaneous coronary intervention (PCI) with stenting, with the aim of preventing stent thrombosis and other major adverse cardiac and c...
Main Author: | |
---|---|
Corporate Author: | |
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
March 2019, 2019
|
Series: | CADTH optimal use report, 1927-0127
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references